Two for the price of two: Cubist fronts $1.24b for Trius, Optimer

Why buy one antibiotic developer when you can buy two? Cubist Pharmaceuticals will spend up to $1.62 billion for Trius Therapeutics and Optimer Pharmaceuticals, whose lead drugs Cubist believes will generate $600 million to $1 billion in combined annual revenue at their peak.